December 2019 archive | MD Anderson Cancer Center

Skip to Content

MyChart

Log in to our secure, personalized website to manage your care (formerly myMDAnderson).
Request an Appointment

If you are ready to make an appointment, select a button on the right. If you have questions about MD Anderson’s appointment process, our information page may be the best place to start.
Appointment Information

New Patients Current Patients Referring Physicians
Donate Today

Top

December 2019 Archive

Immunotherapy clinical trial assesses opportunity to prevent lung...

BY Scott Merville

December 18, 2019

An immunotherapy used against advanced non-small cell lung cancer is being tested at MD Anderson for a different job: preventing the...

An immunotherapy clinical trial uses the immune checkpoint blockade drug pembrolizumab against precancerous growths to prevent their evolution to lung cancer.

A triple-negative breast cancer cell in the process of dying under attack from a combination of drugs in a laboratory experiment. Image: National Cancer Institute

Metastatic cells, mechanisms of drug resistance identified...

BY Jill Russell, Ph.D.

December 12, 2019

Researchers at The University of Texas MD Anderson Cancer Center have discovered important mechanisms of drug resistance and...

Combination therapy key in two studies of blood cancers...

December 06, 2019

Results from two MD Anderson studies demonstrated the significance of combination therapy in follicular lymphoma and chronic...

Immunotherapy innovation: Moon Shots effort aims natural killer...

BY Clayton Boldt, Ph.D.

December 03, 2019

MD Anderson’s adoptive cell therapy (ACT) platform is advancing the next generation of cell-based immune therapies to bring innovative...

Katy Rezvani, M.D., Ph.D., equips innate immune system natural killer cells with a chimeric antigen receptor that targets B cell malignancies, an experimental approach that’s yielded results in early clinical trials. Her lab is developing CAR NK cells against other cancers.